Cipla Limited (NSE:CIPLA)
India
· Delayed Price · Currency is INR | Market Cap | 1.19T |
| Revenue (ttm) | 271.45B |
| Net Income (ttm) | 52.73B |
| Shares Out | 807.64M |
| EPS (ttm) | 65.24 |
| PE Ratio | 22.64 |
| Forward PE | 23.89 |
| Dividend | 13.00 (0.89%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 1,383,631 |
| Average Volume | 1,948,760 |
| Open | 1,475.00 |
| Previous Close | 1,468.50 |
| Day's Range | 1,463.00 - 1,479.50 |
| 52-Week Range | 1,335.00 - 1,702.05 |
| Beta | 0.16 |
| RSI | 46.70 |
| Earnings Date | May 13, 2025 |
About Cipla
Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormaliti... [Read more]
Financial Performance
In 2024, Cipla's revenue was 271.45 billion, an increase of 6.30% compared to the previous year's 255.37 billion. Earnings were 52.73 billion, an increase of 27.93%.
Financial StatementsNews
Citi maintains ‘Buy’ on Cipla; sees 21.5% upside despite rising competition in Abraxane generic
Citi has reiterated a ‘Buy’ rating on Cipla Ltd, assigning a target price of ₹1,800, implying an upside of 21.5% from the current market price of ₹1,481.00 (as of latest close). The brokerage highligh...
Nifty 50 top gainers today, May 21: Bharat Electronics, Tata Steel, Cipla, HDFC Life, Bajaj Finserv and more
Indian equity markets displayed robust performance today, with key benchmark indices closing firmly in the green. The BSE Sensex surged by 410.19 points, a 0.51% increase, to close at 81,596.63. Simil...
Bharti Airtel, Tata Motors & more: Top stocks on brokers' radar today
Citigroup has a buy rating on Bharti Airtel, while CLSA is optimistic about Tata Motors. Morgan Stanley is overweight on GAIL, anticipating increased gas demand. Motilal Oswal has a neutral rating on ...
Nifty 50 top losers today, May 14: Cipla, Asian Paints, Tata Motors, Kotak Mahindra Bank, NTPC and more
Indian stock markets closed on a strong note on May 14. The BSE Sensex rose by 182.34 points or 0.22%, settling at 81,330.56, while the NSE Nifty 50 climbed 88.55 points or 0.36%, ending the session a...
Nomura maintains ‘Buy’ on Cipla, target price Rs 1,760; sees steady FY26 outlook despite Q4 miss
Nomura has reiterated a Buy rating on Cipla shares, with a target price of ₹1,760, suggesting upside from the current market price of ₹1,520.00. While the company reported an EBITDA miss in Q4FY25, th...
Cipla Q4 profit jump 30% to Rs 1,222 crore; Board approves Rs 16 per share dividend
Cipla Ltd reported a robust 30% YoY increase in consolidated net profit, reaching Rs 1,222 crore for Q4 FY25, driven by strong sales in India, the US, and Africa. For the full fiscal year, net profit ...
Cipla Q4 Results: Board declares Rs 16 per share dividend, includes Rs 3 special payout
Cipla Ltd has reported a consolidated net profit of ₹1,221.84 crore for the fourth quarter ended March 31, 2024, marking a strong 30% year-on-year increase from ₹939 crore in Q4 FY23. The company’s re...
Cipla Q4 Results: Revenue jumps 9% YoY to Rs 6,729 crore, Net Profit up 30% YoY
Cipla Ltd has reported a consolidated net profit of ₹1,221.84 crore for the fourth quarter ended March 31, 2024, reflecting a strong 30% year-on-year growth from ₹939 crore in Q4 FY23. The company’s r...
Cipla’s Goa unit gets ‘Voluntary Action Indicated’ classification from USFDA after inspection
Cipla Limited on Thursday announced that the United States Food and Drug Administration (USFDA) has classified its inspection at Medispray Laboratories’ manufacturing facility in Kundaim, Goa as Volun...
Cipla in focus after USFDA approves generic version of blockbuster cancer drug Abraxane
Shares of Cipla Limited rose as much as 3.55% to ₹1,465.90 in early trade on Friday, following the company’s announcement that it has received final approval from the US Food and Drug Administration (...
Cipla receives USFDA approval for Generic Abraxane
Cipla Limited has announced a significant milestone with the final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Paclitaxel P...
Pharma Stocks Falls: Aurobindo Pharma slips 2%, Lupin down 2%, Divi’s Labs falls 3% as Trump reiterates tariffs on pharmaceuticals ‘soon’
Indian pharmaceutical stocks declined in early trade on Wednesday following renewed concerns over potential U.S. import tariffs. At 9:36 AM, Aurobindo Pharma shares were down 2% to ₹1,073.15, Dr. Redd...
Cipla: Business Model, Q3 FY25 Earnings, Promoter Details, and Shareholding Pattern
Cipla Limited, a Mumbai-based global pharmaceutical company, has been a prominent player in India’s healthcare sector since its founding in 1935. As of April 05, 2025, Cipla continues to focus on manu...
Nifty 50 top losers today, April 4: Tata Steel, Hindalco Industries, ONGC, Tata Motors, Cipla and more
Indian equity markets continued their downward trajectory for the second straight session on April 4, 2025, as fears of a global trade war intensified following U.S. President Donald Trump’s announcem...
Cipla shares drop over 6% after Trump hints at pharma tariffs; heavy U.S. exposure adds pressure
Shares of Cipla Ltd fell 6.08% to ₹1,404.70 on Friday, declining ₹91.00 from the previous close of ₹1,495.70, as renewed fears of U.S. pharmaceutical import tariffs rattled investors. The stock had ga...
Nifty 50 top gainers today, April 3: Power Grid, Sun Pharmaceutical, Cipla, UltraTech and more
The Indian equity market witnessed a downturn on April 3, as both the Sensex and Nifty 50 closed in the red following the announcement of fresh U.S. tariffs. The benchmark Sensex dropped 322.08 points...
Cipla shares gain over 4.5% as U.S. excludes Indian pharma exports from tariff list; Nomura, Jefferies upbeat on outlook
Shares of Cipla Ltd climbed 4.55% to ₹1,518.40 in early trade on April 3, joining the broader rally in Indian pharma stocks after the U.S. government excluded pharmaceuticals from the 26% reciprocal t...
Pharma and healthcare stocks: Macquarie turns bullish on Sun Pharma, Cipla, Lupin; bearish on Apollo Hospitals, Max Healthcare
Macquarie believes the recent correction in pharmaceutical formulation stocks triggered by tariff-related concerns presents a compelling buying opportunity. In its latest sector note, the brokerage ha...
Nifty 50 top losers this week: Zomato, IndusInd Bank, Cipla, Mahindra & Mahindra and more
The Indian stock market extended its winning streak for the second consecutive week, with both the Sensex and Nifty gaining around 1% each. However, despite the overall strong performance, the markets...
Nifty 50 top losers today, March 28: Wipro, IndusInd Bank, Shriram Finance, Cipla and more
Indian equity indices witnessed a volatile trading session on March 28, with the BSE Sensex slipping 191.51 points (0.25%) to settle at 77,414.92, while the NSE Nifty 50 declined 72.60 points (0.31%),...
Nifty 50 top losers today, March 26: NTPC, Tech Mahindra, Cipla, Bajaj Finance and more
The Indian stock market ended in the red on Wednesday as both Sensex and Nifty reversed their early gains. The benchmark indices, which opened on a positive note for the eighth consecutive session, to...
Cipla signs pact with Taiwan drug firm
India Business News: Cipla has announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals to market clobetasol propionate ophthalmic suspension 0.
Cipla and Formosa Pharmaceuticals sign multi-regional licensing deal for clobetasol suspension
Cipla Limited has entered into an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals to commercialize clobetasol propionate ophthalmic suspension, 0.05% across 11 countries. This ...
Nifty 50 top gainers today, March 13: Bharat Electronics, State Bank of India, ONGC, Cipla and more
On March 13, Indian equity indices ended on a negative note, with the benchmark indices struggling to maintain upward momentum. The BSE Sensex dropped 200.85 points or 0.27% to close at 73,828.91, whi...
Macquarie bullish on select pharma and CDMO stocks, bearish on hospitals
Macquarie believes that the recent correction in pharma stocks due to US tariff threats provides an attractive buying opportunity, particularly in formulations and CDMO (Contract Development and Manuf...